secwatch.observer — SEC 8-K summary
======================================

Issuer:     Revolution Medicines, Inc. (RVMD)
CIK:        0001628171
Form:       8-K
Filed at:   2024-05-08T23:59:59+00:00
Accession:  0000950170-24-055606
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Revolution Medicines Q1 net loss $116M; cash $1.70B; plans pivotal RMC-6236 trials in H2 2024
--------------------------------------------------------------------------------

- Net loss of $116.0M for Q1 2024, compared to $68.1M in Q1 2023.
- Revenue $0 (ended Sanofi collaboration); R&D expenses $118.0M (up from $68.9M).
- Cash $1.70B as of March 31, 2024; projected cash runway into 2027.
- Plans to initiate two pivotal monotherapy trials of RMC-6236 in 2L PDAC and 2L NSCLC in H2 2024.
- Reiterates FY2024 GAAP net loss guidance between $480M and $520M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1628171/000095017024055606/0000950170-24-055606-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1628171/000095017024055606/rvmd-20240508.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-055606

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer